InsidersTradesSigma
Track the EyePoint Pharmaceuticals, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, EyePoint Pharmaceuticals, Inc. has published 108 insider filings. Market capitalisation: €1.1bn. The latest transaction was disclosed on 5 December 2025 (Cession). Among the most active insiders: Lurker Nancy. All data is free.
108
Insider Decl.
n/a
Thresholds
€31m
12 ops.
Buy Volume
€101m
18 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate EyePoint Pharmaceuticals, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$40.50.
53Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,826 of 29,064 companies
29.2
score / 100
Value10
Quality49
FCF yld-22%
Earn yld-21%
EV/EBITDA·
ROE-149%
Gross mgn93%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 December 2025
Declarations108 total
9,300 shares@ US$15.105114.7% of flowCommon StockSEC:0001450485-25-000009:0
200 shares@ US$14.950.4% of flowCommon StockSEC:0001450485-25-000007:0
2,722 shares@ US$11.61100.0% of flowCommon StockSEC:0002013623-25-000005:0
20,000 shares0Common StockSEC:0001429932-25-000005:0
2,000 shares0Common StockSEC:0001562180-25-005391:0
11,111 shares0Common StockSEC:0001562180-25-005390:0
16,667 shares0Common StockSEC:0001562180-25-005389:0
56,665 shares@ US$8.2178.1% of flowCommon StockSEC:0001562180-25-005074:0
7,500 shares0Common StockSEC:0001562180-25-004193:0
2,202 shares@ US$5.68100.0% of flowCommon StockSEC:0001562180-25-004193:1
5,000 shares@ US$5.8118.5% of flowCommon StockSEC:0001562180-25-003997:0
Canonical exit: 14 Aug 2025 (T+90)
5,000 shares@ US$5.4217.3% of flowCommon StockSEC:0001562180-25-003873:0
Canonical exit: 12 Aug 2025 (T+90)
20,000 shares@ US$6.155100.0% of flowCommon StockSEC:0001562180-25-002626:0
5,834 shares0Common StockSEC:0001562180-25-001135:0
7,000 shares0Common StockSEC:0001562180-25-001133:0
20,000 shares0Common StockSEC:0001562180-25-001134:0
12,667 shares0Common StockSEC:0001562180-25-000228:0
15,000 shares0Common StockSEC:0001562180-25-000229:0
30,000 shares0Common StockSEC:0001562180-25-000226:0
10,000 shares0Common StockSEC:0001562180-25-000227:0
5,000 shares@ US$7.95100.0% of flowCommon StockSEC:0001562180-24-006432:0
Canonical exit: 19 Nov 2024 (T+90)
2,567 shares@ US$7.79100.0% of flowCommon StockSEC:0001562180-24-006440:0
Canonical exit: 18 Nov 2024 (T+90)
12,500 shares@ US$7.9864.2% of flowCommon StockSEC:0001562180-24-006431:0
Canonical exit: 17 Nov 2024 (T+90)
3,173 shares@ US$7.882.6% of flowCommon StockSEC:0001562180-24-006378:0
Canonical exit: 14 Nov 2024 (T+90)
3,250 shares@ US$3.5021.1% of flowCommon StockSEC:0001562180-24-005752:0
25 of 108 declarations
关于 EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 是一家总部位于美国马萨诸塞州沃特敦的美国生物制药公司。该公司专注于眼科领域，特别侧重于视网膜疾病和眼内炎症。对于投资者而言，EyePoint 最好被视为一家专业生物技术公司，而非一家多元化的综合制药公司：其商业模式的核心是开发、临床去风险、选择性商业化并最终通过专有的长效眼部给药技术实现货币化。 该公司的历史包括早期的公司迭代和名称变更，例如在 2018 年 3 月采用 EyePoint Pharmaceuticals 名称之前，其前身为 pSivida Corp.。这一转变反映了公司战略向更专注的视网膜和眼科特许经营权的转变。EyePoint 还在马萨诸塞州诺斯布里奇设有生产基地，支持专业眼科产品的生产控制，并巩固其在美国的运营基础。 EyePoint 的商业产品组合历来包括 DEXYCU（一种用于白内障手术后炎症的玻璃体内地塞米松混悬液）和 YUTIQ（一种用于慢性非感染性后葡萄膜炎的氟轻松玻璃体内植入物）。这些已上市产品展示了公司在缓释眼科制剂方面的专业知识。在竞争方面，EyePoint 与传统的注射疗法和其他给药方法竞争，并通过给药便利性、延长作用持续时间以及改善依从性和患者预后的潜力来寻求差异化。 该公司下一代价值驱动因素是 DURAVYU™（前身为 EYP-1901），这是一种基于 EyePoint 专有 Durasert 平台的沃罗拉尼玻璃体内植入物。DURAVYU 正在开发作为湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的持续给药疗法。管理层将其定位为一种可能具有差异化的视网膜资产，旨在减轻治疗负担并支持更持久的治疗效果。EyePoint 还通过 Ocumension Therapeutics 等公司在大中华区以外的地区建立战略合作伙伴关系，以扩大其资产的潜在商业范围。 最近的亮点在临床上具有重要意义。2025 年，EyePoint 宣布完成 DURAVYU 治疗湿性 AMD 的关键性 3 期项目入组，并报告了糖尿病性黄斑水肿的积极 2 期数据。这些里程碑支持了围绕 DURAVYU 和更广泛的 Durasert 平台的投资论点，尽管该公司仍面临重大的临床、监管、商业化和融资风险。总体而言，EyePoint 是一家在纳斯达克上市的美国专业眼科公司，具有重要的管线选择权，但仍应将其评估为一项对执行敏感的临床阶段项目，而非一个成熟的现金生成平台。
